Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-12-12
2006-12-12
Chan, Christina (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S063000, C435S375000, C435S252300, C514S04400A, C536S024500
Reexamination Certificate
active
07148014
ABSTRACT:
The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.
REFERENCES:
patent: 4686282 (1987-08-01), Hahn
patent: 4902681 (1990-02-01), Schreiber
patent: 4908358 (1990-03-01), Schreiber
patent: 5075321 (1991-12-01), Schreiber
patent: 5189014 (1993-02-01), Cowan, Jr.
patent: 5641875 (1997-06-01), Schreiber et al.
patent: 5776910 (1998-07-01), Schreiber et al.
patent: 5821071 (1998-10-01), Schreiber et al.
patent: 5858981 (1999-01-01), Schreiber et al.
patent: 6068983 (2000-05-01), Schreiber et al.
patent: 6242427 (2001-06-01), Schreiber et al.
patent: 6475997 (2002-11-01), Schreiber et al.
patent: 6610674 (2003-08-01), Schreiber
patent: 6638764 (2003-10-01), Schreiber et al.
patent: 6844333 (2005-01-01), Schreiber
patent: 701919 (1995-04-01), None
patent: 0 614 978 (1994-09-01), None
patent: 0 723 455 (1996-07-01), None
patent: WO 91/06570 (1991-05-01), None
patent: WO 93/21317 (1993-10-01), None
patent: WO 95/09002 (1995-04-01), None
patent: WO 95/09011 (1995-04-01), None
US 6,979,678, 12/2005, Schreiber et al. (withdrawn)
Mountain in TIBTECH (18:119-128 2000.
Bals R., et al., nfection and Immunity, 1999, v.67, pp. 6084-6089.
Cochlovius et al., Modern Drug Discovery, 2003, pp. 33-38.
Letourneur et al, “Characterization of the Family of Dimers Associated with Fc Receptors (FcεRI FcγRIII)”, The Journal of Immunology 147(8):2652-2656 (1991).
Takai et al., FcRγ Chain Detection Results in Pleiotrophic Effector Cell Defects, Cell 76:519-529 (1994).
Turner et al, “Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk”, Nature 378:298-306 (1995).
Porteous et al, “Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis”, Gene Therapy 4:210-218 (1997).
Bonn, “Prospects for antisense therapy are looking brighter”, Science and Medicine 347:820-821 (1996).
Stein et al, “Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical”, Science 261:1004-1012 (1993).
Roush, “Antisense Aims for a Renaissance”, Science 276:1192-1193 (1997).
Alton et al, “Non-invasive liposome-meidated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice”, Nature Genetics 5:135-142 (1993).
Chan et al, “Differential Expression of ZAP-70 and Syk Protein Tyrosine Kinases, and the Role of This Family of Protein Tyrosine Kinases in TCR Signaling”, Journal of Immunology, pp. 4758-4766 (1994).
Zelphati t al, “Intracellular Distribution and Mechanism of Delivery of Oligonucleotides Mediated by Cationic Lipids,” Pharmaceutical Research 13(9):1367-1372 (1996).
Stull et al, “Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects”, Pharmaceutical Research 12(4):465-483 (1995).
Maekawa et al, “Induction of Fc epsilon RII/CD23 on PHA-activated human peripheral blood T lymphocytes and association of fyn tyrosine kinase with Fc epsilon RII/CD23”, Int. J. Tissue React. 14(3):121-130 (1992)—Abstract.
Sugie et al, “Fyn tyrosine kinase associated with Fc epsilon RII/CD23: possible multiple roles in lymphocyte activation”, Proc. Natl. Acad. Sci. USA 88(20):9132-9135 (1991)—Abstract.
Richards et al, “Biology and chemistry of low affinity IgE receptor (Fc epsilon RII/CD23)”, Crit. Rev. Immunol. 11 (2):65-86 (1991)—Abstract.
Yodoi et al, “Low affinity IgE receptors: regulation and functional roles in cell activation”, Ciba Found. Symp. 147:133-148 (1989)—Abstract.
Mehta et al, “Eosinophil as a therapeutic target in allergic disease”, Compr. Ther. 20(11):651-657 (1994)—Abstract.
Kiehntopf et al, “Ribozyme-mediated cleavage of theMDR-1transcript restores chemosensitivity in previously resistant cancer cells”, The EMBO Journal 13(19):4645-4652 (1994).
Akhtar et al, “Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)”, Nucleic Acids Research 19(20):5551-5559 (1991).
Thierry et al, “Overcoming Multidrug Resistance in Human Tumor Cells Using Free and Liposomally Encapsulated Antisense Oligonucleotides”, Biochemical and Biophysical Research Communication 190(3):952-960 (1993).
Zelphati et al, “Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms”, Nucleic Acids Researchs 22(20):4307-4317 (1994).
Aoki et al, “Liposome-mediatedin VivoGene Transfer of Antisense K-rasConstruct Inhibits Pancreatic Tumor Dissemination in the Murine Peritoneal Cavity”, Cancer Research 55:3810-3816 (1995).
Lewis et al, “A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA”, Proc. Natl. Acad. Sci USA 93:3176-3181 (1996).
Sugimoto et al, “Oligomannose-coated liposomes as an adjuvant for the induction of cell-mediated immunity”, FEBS Letters 363:53-56 (1995).
Grimaldi et al, “Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection”, Res. Virol. 148:177-180 (1997).
Wang et al, “Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol”, Proc. Natl. Acad. Sci. USA 92:3318-3322 (1995).
Koff et al, “Protection of Mice Against Fatal Herpes Simplex Type 2 Infection by Liposomes Containing Muramyl Tripeptides”, Science , pp. 495-497 (Apr. 26, 1985).
Ohishi et al, “Peptide-Based Bovine Leukemia Virus (BLV) Vaccine That Induces BLV-Env Specific Th-1 Type Immunity”, Leukemia 11: Suppl. 223-226 (1997).
Francis et al, “Efficacy of Unilamellar Liposomal Amphotericin B in Treatment of Pulmonary Aspergillosis in Persistently Granulocytopenic Rabbits: The Potential Role of Bronchoalveolar D-Mannitol and Serum Galactomannan as Markers of Infection”, The Journal of Infectious Diseases 169:356-368 (1994).
Demoly et al, “IgE produces monocyte superoxide anion release Correlation with CD23 expression”, J. Allergy Clin. Immunol. 93(1)/Part 1:108-116 (1994).
Vignola et al, “Phenotypic and Functional Modulation of Normal Human Alveolar Macrophages by Histamine”, Am. J. Respir. Cell Mol. Biol. 11:456-463 (1994).
Inagaki, “An Increase in Superoxide Generation of Bronchoalveolar Lavage Fluids in the Model of Late Asthmatic Response in Guinea Pigs”, Journal of Asthma 30(5):401-405 (1993).
Jarjour et al, “Enhanced production of oxygen radicals in asthma”, J. Lab. Clin. Med. 123:131-136 (1994).
Vachier et al, “Imaging Reactive Oxygen Species in Asthma”, J. Biolumin. Chemilumin. 9:171-175 (1994).
Curtis et al, “New Concepts in the Pathogenesis of Immune Lung Injury”, Seminars in Respiratory Medicine 12(3):156-174 (1991).
Hallsworth et al, “Selective enhancement of GM-CSF, TNF-α, IL-1β and IL-8 production by monocytes and macrophages of asthmatic subjects”, Eur. Respir. J. 7:1096-1102 (1994).
Callerame et al, “Immunologic Reactions of Bronchial Tissues in Asthma”, The New England Journal of Medicine 284(9):459-463 (1971).
Wasserman, “Mast Cells and Airway Inflammation in Asthma”, Am. J. Respir. Cri. Car
Park Jong-Gu
Schreiber Alan D.
Belyavskyi Michail A.
Chan Christina
University of Pennsylvania
LandOfFree
Methods of inhibiting phagocytosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting phagocytosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting phagocytosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718275